Indications

Twenty-five years of extensive research has led to a dramatic increase in our understanding of the pathophysiology of diabetic metabolism. Metabolic Activation Therapy (MAT) has evolved as the only therapy in existence which has been proven to arrest and even reverse the common life-threatening complications of diabetes. Through extensive research, including multi-institutional studies performed in such prestigious institutions such as the Joslin Clinic, Mayo Clinic, Scripps Clinic, Summit Medical Center of Nashville, University of Arizona, University of Maryland, and University of California, Davis, MAT has revolutionized our understanding and treatment of these seriously ill patients.

Current indications for MAT which have not only been proven in exhaustive clinical studies, but have also stood the inevitable reimbursement challenges in the court system are as follows:

1. Glycemic Control - Metabolic Activation is indicated for patients who despite their best efforts continue to experience unanticipated large swings in blood glucose levels, resulting in frequent episodes of hypoglycemia/hyperglycemia. It is indicated in patients requiring frequent hospitalization due to diabetic ketoacidosis. It is indicated in patients suffering from frequent severe hypoglycemic episodes with hypoglycemic unawareness.

2. Diabetic Nephropathy - Metabolic Activation is indicated when despite intensive oral hypoglycemic agent and/or insulin therapy and blood pressure control with ACE inhibitors, the patient’s renal function continues to decline.

3. Orthostatic Hypotension - Metabolic Activation is indicated when the patient with diabetes has orthostatic hypotension not treatable by other therapies.

4. Gastroparesis - Metabolic Activation is indicated for patients with gastroparesis associated with diabetes not relieved by other drug or dietary therapies.

5. Painful Peripheral Neuropathy - Metabolic Activation is indicated for patients with painful peripheral neuropathy not relieved by conventional state-of-the-art intensive therapy and/or analgesics.

6. Retinopathy - Metabolic Activation is indicated for patients with background or proliferative neuropathy.

7. Wound Healing - Metabolic Activation is indicated for treatment of non-gangrenous, non-healing leg ulcers not complicated by osteomyelitis, not responsive to other therapies.

Further experience with MAT is destined to expand the above indications. Active clinical research is an integral part of MAT and is coordinated through the Aoki Diabetic Research Institute.